Market Overview

ICON Named by Forbes as One of the Best Employers in America


, (NASDAQ:ICLR) a global provider of drug development
solutions and services to the pharmaceutical, biotechnology and medical
device industries, today announced that it has been included in Forbes
magazine's America's
Best Employers
list for 2017

Now in its third year, the Forbes list features the top 500 large
employers in the US with more than 5,000 employees and the top 300
midsize companies with 1,000 – 5,000 employees. ICON was the highest
ranked CRO in the best midsize employers listing.

The Forbes list is determined following an independent, online survey of
30,000 employees representing companies from 25 industry sectors. In
conjunction with consumer research provider, Statista,
employees were consulted anonymously in September 2016 through several
online panels to allow them to share their opinions about their
employers openly and without any influence from their employer.
Respondents were asked to rate their willingness to recommend their own
companies on a scale of 0 – 10 and were also asked to name good and bad
employers in industry sectors other than their own.

"We are proud to be named by Forbes as one of the best employers in
America and we are pleased that our employees are recommending ICON as
an excellent place to work," commented Dr. Steve Cutler, Chief Executive
Officer, ICON. "We have great people who are committed to helping our
clients to accelerate the development of drugs and devices that are
saving lives and improving the quality of life of patients right across
the globe. We will continue to work hard to ensure that we provide a
work environment that engages, rewards and develops our employees so
that they can build successful careers at ICON."

About ICON

ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 87 locations in 38 countries and
has approximately 12,300 employees. Further information is available at

This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at


View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at